vs
Side-by-side financial comparison of Bluerock Homes Trust, Inc. (BHM) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $18.9M, roughly 1.2× Bluerock Homes Trust, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -50.1%, a 57.4% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 35.9%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 30.1%).
Bluerock Homes Trust, Inc. is a U.S.-headquartered real estate investment trust that acquires, owns and operates a portfolio of high-quality single-family rental residential properties. It caters to middle-market renters across high-growth suburban markets, prioritizing regions with strong demographic fundamentals and sustained rental housing demand.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
BHM vs CUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $21.9M |
| Net Profit | $-9.5M | $1.6M |
| Gross Margin | — | — |
| Operating Margin | -48.8% | 9.0% |
| Net Margin | -50.1% | 7.2% |
| Revenue YoY | 35.9% | 1292.3% |
| Net Profit YoY | -29.9% | 116.7% |
| EPS (diluted) | $-0.75 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.9M | $21.9M | ||
| Q3 25 | $16.6M | $2.1M | ||
| Q2 25 | $16.8M | $3.0M | ||
| Q1 25 | $16.4M | $421.0K | ||
| Q4 24 | $13.9M | $1.6M | ||
| Q3 24 | $12.7M | $3.3M | ||
| Q2 24 | $12.5M | $2.7M | ||
| Q1 24 | $11.2M | $1.7M |
| Q4 25 | $-9.5M | $1.6M | ||
| Q3 25 | $-10.0M | $-7.4M | ||
| Q2 25 | $-5.8M | $-8.5M | ||
| Q1 25 | $-7.3M | $-12.3M | ||
| Q4 24 | $-7.3M | — | ||
| Q3 24 | $3.5M | $-8.7M | ||
| Q2 24 | $-5.2M | $-10.2M | ||
| Q1 24 | $-3.2M | $-12.3M |
| Q4 25 | -48.8% | 9.0% | ||
| Q3 25 | -57.6% | -353.4% | ||
| Q2 25 | -30.9% | -292.3% | ||
| Q1 25 | -42.6% | -2921.4% | ||
| Q4 24 | -52.8% | — | ||
| Q3 24 | 27.9% | -264.2% | ||
| Q2 24 | -41.3% | -390.6% | ||
| Q1 24 | -28.4% | -737.8% |
| Q4 25 | -50.1% | 7.2% | ||
| Q3 25 | -60.0% | -346.6% | ||
| Q2 25 | -34.7% | -287.1% | ||
| Q1 25 | -44.7% | -2911.4% | ||
| Q4 24 | -52.8% | — | ||
| Q3 24 | 27.9% | -259.6% | ||
| Q2 24 | -41.3% | -382.7% | ||
| Q1 24 | -28.4% | -719.1% |
| Q4 25 | $-0.75 | $0.05 | ||
| Q3 25 | $-0.94 | $-0.07 | ||
| Q2 25 | $-0.66 | $-0.09 | ||
| Q1 25 | $-0.67 | $-0.17 | ||
| Q4 24 | $-0.65 | — | ||
| Q3 24 | $0.24 | $-0.17 | ||
| Q2 24 | $-0.42 | $-0.20 | ||
| Q1 24 | $-0.27 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $169.6M | $27.1M |
| Total DebtLower is stronger | $428.4M | — |
| Stockholders' EquityBook value | $128.7M | $26.4M |
| Total Assets | $1.2B | $42.2M |
| Debt / EquityLower = less leverage | 3.33× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $169.6M | $27.1M | ||
| Q3 25 | $2.1M | $11.7M | ||
| Q2 25 | $4.2M | $27.5M | ||
| Q1 25 | $3.0M | $13.1M | ||
| Q4 24 | $115.2M | $22.5M | ||
| Q3 24 | $155.1M | $32.4M | ||
| Q2 24 | $116.0M | $30.0M | ||
| Q1 24 | $92.3M | $41.0M |
| Q4 25 | $428.4M | — | ||
| Q3 25 | $415.9M | — | ||
| Q2 25 | $338.6M | — | ||
| Q1 25 | $336.5M | — | ||
| Q4 24 | $373.8M | — | ||
| Q3 24 | $122.5M | $1.0M | ||
| Q2 24 | $119.7M | $2.0M | ||
| Q1 24 | $120.2M | $3.0M |
| Q4 25 | $128.7M | $26.4M | ||
| Q3 25 | $131.7M | $13.2M | ||
| Q2 25 | $135.3M | $18.2M | ||
| Q1 25 | $137.1M | $6.6M | ||
| Q4 24 | $139.1M | $17.5M | ||
| Q3 24 | $142.9M | $25.4M | ||
| Q2 24 | $142.5M | $21.6M | ||
| Q1 24 | $144.5M | $30.0M |
| Q4 25 | $1.2B | $42.2M | ||
| Q3 25 | $222.1M | $31.6M | ||
| Q2 25 | $220.3M | $40.7M | ||
| Q1 25 | $186.2M | $22.3M | ||
| Q4 24 | $967.0M | $32.2M | ||
| Q3 24 | $800.8M | $44.8M | ||
| Q2 24 | $756.2M | $42.3M | ||
| Q1 24 | $727.4M | $54.0M |
| Q4 25 | 3.33× | — | ||
| Q3 25 | 3.16× | — | ||
| Q2 25 | 2.50× | — | ||
| Q1 25 | 2.45× | — | ||
| Q4 24 | 2.69× | — | ||
| Q3 24 | 0.86× | 0.04× | ||
| Q2 24 | 0.84× | 0.09× | ||
| Q1 24 | 0.83× | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.8M | $-1.1M |
| Free Cash FlowOCF − Capex | $10.4M | — |
| FCF MarginFCF / Revenue | 55.0% | — |
| Capex IntensityCapex / Revenue | 91.8% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | $25.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.8M | $-1.1M | ||
| Q3 25 | $13.4M | $-9.0M | ||
| Q2 25 | $13.9M | $-3.4M | ||
| Q1 25 | $951.0K | $-8.2M | ||
| Q4 24 | $9.1M | $-36.3M | ||
| Q3 24 | $1.7M | $-7.5M | ||
| Q2 24 | $1.3M | $-10.0M | ||
| Q1 24 | $1.1M | $-9.8M |
| Q4 25 | $10.4M | — | ||
| Q3 25 | $8.7M | — | ||
| Q2 25 | $8.8M | $-3.4M | ||
| Q1 25 | $-2.9M | $-8.3M | ||
| Q4 24 | $-253.0K | $-36.4M | ||
| Q3 24 | $-601.0K | $-7.5M | ||
| Q2 24 | $-654.0K | $-10.0M | ||
| Q1 24 | $-630.0K | $-9.8M |
| Q4 25 | 55.0% | — | ||
| Q3 25 | 52.4% | — | ||
| Q2 25 | 52.2% | -116.5% | ||
| Q1 25 | -17.6% | -1976.7% | ||
| Q4 24 | -1.8% | -2309.3% | ||
| Q3 24 | -4.7% | -225.7% | ||
| Q2 24 | -5.2% | -376.2% | ||
| Q1 24 | -5.6% | -573.0% |
| Q4 25 | 91.8% | 0.0% | ||
| Q3 25 | 28.5% | 0.0% | ||
| Q2 25 | 30.3% | 0.9% | ||
| Q1 25 | 23.4% | 35.6% | ||
| Q4 24 | 66.9% | 4.2% | ||
| Q3 24 | 18.0% | 0.0% | ||
| Q2 24 | 15.3% | 0.4% | ||
| Q1 24 | 15.5% | 3.2% |
| Q4 25 | — | -0.68× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHM
| Residential Communities Segment | $11.4M | 61% |
| Scattered Single Family Homes Segment | $7.5M | 39% |
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
